Advertisement

Regulatory Considerations on the Development, Evaluation, and Approval of Therapies in Rheumatoid Arthritis Prevention

      Perhaps the greatest promise of modern medicine is not that we may eventually be able to treat or cure nearly all diseases but rather that we will routinely be able to prevent or significantly delay the phases of disease in which clinically apparent tissue injury and disease occur. An example is the treatment of elevated cholesterol levels to prevent or delay future myocardial infarction. Indeed, in rheumatoid arthritis (RA), several trials are completed or underway that are evaluating the efficacy and safety of pharmacologic interventions to prevent or delay the future development of clinically apparent inflammatory arthritis.
      • Cope A.P.
      Emerging therapies for pre-RA.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Cope A.P.
        Emerging therapies for pre-RA.
        Best Pract Res Clin Rheumatol. 2017; 31: 99-111
        • Lin J.S.
        • Evans C.V.
        • Johnson E.
        • Redmond N.
        • Coppola E.L.
        • Smith N.
        Nontraditional risk factors in cardiovascular disease risk assessment: updated evidence report and systematic review for the US Preventive Services Task Force.
        JAMA. 2018; 320: 281-297
        • Viswanathan M.
        • Reddy S.
        • Berkman N.
        • et al.
        Screening to prevent osteoporotic fractures: updated evidence report and systematic review for the US Preventive Services Task Force.
        JAMA. 2018; 319: 2532-2551
        • Fenton J.J.
        • Weyrich M.S.
        • Durbin S.
        • Liu Y.
        • Bang H.
        • Melnikow J.
        Prostate-specific Antigen-Based Screening for Prostate Cancer: A Systematic Evidence Review for the US Preventive Services Task Force. US Preventive Services Task Force Evidence Syntheses, Formerly Systematic Evidence Reviews.
        2018 (Rockville (MD))
        • Pignatti F.
        • Jonsson B.
        • Blumenthal G.
        • Justice R.
        Assessment of benefits and risks in development of targeted therapies for cancer—the view of regulatory authorities.
        Mol Oncol. 2015; 9: 1034-1041
        • Insel R.A.
        • Dunne J.L.
        • Atkinson M.A.
        • et al.
        Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association.
        Diabetes Care. 2015; 38: 1964-1974
        • Harrison M.
        • Spooner L.
        • Bansback N.
        • et al.
        Preventing rheumatoid arthritis: preferences for and predicted uptake of preventive treatments among high risk individuals.
        PLoS One. 2019; 14e0216075
        • Calonge N.
        Developing evidence-based screening recommendations, with consideration for rheumatology.
        Rheum Dis Clin North Am. 2014; 40: 787-795
        • Van Norman G.A.
        Drugs and devices: comparison of European and US approval processes.
        JACC Basic Transl Sci. 2016; 1: 399-412
        • Gerlag D.M.
        • Raza K.
        • van Baarsen L.G.
        • et al.
        EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis.
        Ann Rheum Dis. 2012; 71: 638-641
        • van Steenbergen H.W.
        • Aletaha D.
        • Beaart-van de Voorde L.J.
        • et al.
        EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis.
        Ann Rheum Dis. 2017; 76: 491-496